HIV-1

Some Cord Blood Stem Cells Are Not Susceptible to HIV-1 Infection

Published in AIDS Weekly, February 21st, 2000

It may be possible to use certain human placental cord blood stem cells and their progeny to design gene therapy for perinatal HIV-1 infection, according to researchers in the United States.

The AC133 is a novel antigen selectively expressed on primitive CD34^bright stem cells and is a valuable marker for the selection of long-term culture-initiating cells and severe combined immunodeficiency-repopulating cells. Human placental cord blood (HPCB) is a rich source of CD34⁺AC133⁺ cells, noted Y. Li and colleagues.

Li et al. examined the susceptibility of HPCB-isolated CD34⁺AC133⁺ stem cells to HIV-1...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-02-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry